Citrate-derived acetyl-CoA partitioning as a metabolic-epigenetic checkpoint in cancer

Background Cancer metabolism is usually interpreted through production rates, metabolite concentrations and pathway activities. For citrate-derived acetyl units, this view may be incomplete because the biological consequence of an acetyl group depends on its source, compartment and destination. Hypothesis We propose, rather than assume as established, that in a subset of cancers the routing of citrate-derived acetyl units can function as a metabolic-epigenetic decision point. Citrate exported through SLC25A1 and cleaved by ATP-citrate lyase (ACLY) can contribute to nuclear acetylation, fatty-acid synthesis, sterol synthesis and other acetyl-unit fates. When citrate-derived acetyl-CoA is a quantitatively important source and local nuclear compensation is limited, expansion of lipid-synthetic demand may lower the fraction of citrate-derived acetyl units reaching chromatin. Whether this affects differentiation, proliferation or oncogenic transcription is expected to depend on enhancer identity and acetyltransferase competence. Evidence considered We synthesize published work on non-canonical tricarboxylic-acid-cycle wiring, SLC25A1-ACLY-dependent acetyl-CoA generation, compartmentalized acyl-CoA metabolism, ACSS2 and nuclear pyruvate dehydrogenase, lipid and sterol biosynthesis, oncogenic signaling, and metabolism-sensitive histone acetylation. These studies establish the components of the model but do not directly demonstrate competitive allocation of the same citrate-derived acetyl units between lipid and chromatin destinations as a causal determinant of cancer-cell differentiation. Conclusions The proposed checkpoint remains a hypothesis. Its value is to specify a source-resolved mass balance and a set of experiments that distinguish reduced acetyl-CoA supply from redistribution among destinations. A decisive test requires isotope-resolved carbon tracing, SLC25A1/ACLY and alternative-source perturbation, measurement of fatty-acid and sterol products, validated nuclear metabolomics, broader histone-acetylation profiling, enhancer-resolved chromatin assays and causal epistasis. The framework is therefore intended as a falsifiable experimental model, not as an established mechanism or current therapeutic principle.